Understanding the natural history of KSHV-associated Multicentric Castleman Disease
Natural History Study of KSHV-Associated Multicentric Castleman's Disease
This study looks at how KSHV-associated Multicentric Castleman Disease affects people over time to see if current treatments work and to find better options for those living with this condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 195 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Drugs / interventions | rituximab, chemotherapy, doxorubicin |
| Locations | 1 site (Bethesda, Maryland) |
| Trial ID | NCT04968288 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the natural history and biology of KSHV-associated Multicentric Castleman Disease (MCD), a rare and severe condition often seen in HIV-infected individuals. By examining the disease's progression and the effectiveness of existing treatments, the study seeks to enhance understanding of how KSHV-MCD affects patients and to identify potential new therapeutic strategies. The research will involve patients with biopsy-proven KSHV-MCD and will assess their health outcomes over time. The findings may contribute to improved treatment protocols for this challenging condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with biopsy-proven KSHV-associated Multicentric Castleman Disease.
Not a fit: Patients with conditions that make participation unsafe or inappropriate, as well as pregnant individuals, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better treatment options and improved survival rates for patients with KSHV-associated Multicentric Castleman Disease.
How similar studies have performed: Previous studies have shown promising results in understanding and treating KSHV-associated conditions, indicating that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: * Biopsy proven KSHV-associated MCD, confirmed in the Laboratory of Pathology (LP), CCR * Age \>=18 years. * ECOG performance status \<=4 (Karnofsky \>=20%). * Ability of subject to understand and the willingness to sign a written informed consent document. * Participants may be co-enrolled in other protocols, including investigational studies to treat KSHV-associated malignancies. EXCLUSION CRITERIA: * Any condition or set of circumstances that in the opinion of the investigators would make participation in this study unsafe or otherwise inappropriate for a given individual. * Pregnancy
Where this trial is running
Bethesda, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Ramya M Ramaswami, M.D. — National Cancer Institute (NCI)
- Study coordinator: Irene B Ekwede, R.N.
- Email: irene.ekwede@nih.gov
- Phone: (240) 760-6126
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.